Published online Dec 21, 2013. doi: 10.3748/wjg.v19.i47.8861
Revised: October 29, 2013
Accepted: November 28, 2013
Published online: December 21, 2013
Core tip: Recent advances in treatment modalities have improved the survival rate of patients with hepatocellular carcinoma (HCC). However, hepatitis B virus (HBV)-related HCC has a much higher recurrence rate. In this article, we describe strategies for reducing recurrent HCC using anti-viral therapy for HBV infection.